Learn more about whether Legend Biotech Corporation or Protagonist Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Learn more about whether Halozyme Therapeutics, Inc. or Twist Bioscience Corporation is a better investment based on AAII's ...

Shares of Incyte (INCY) fell 6% Monday after the company released its Q4 earnings report and 2025 sales forecast. Read more ...

Prothena (NASDAQ:PRTA – Free Report) had its price target boosted by Oppenheimer from $58.00 to $62.00 in a report published on Friday,Benzinga reports. They currently have an outperform rating on the ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Gilead to report Q4 earnings on Feb. 11, with analysts expecting $1.70 EPS ... s GAAP and non-GAAP 2025 EPS by approximately ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

Illumina's revenue has stagnated or declined for several years now, and its total sales for 2024 were $4.3 billion, down from ...

Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The monthly jobs report showed hiring slowed in January and the U.S. created fewer jobs than economists expected. The unemployment rate ticked down to 4%. Follow along for live updates on stocks and ...

Amgen's dividend yield remains attractive, with a moderate payout ratio and strong free cash flow. Click here to see why AMGN ...